Pregabalin Capsule
Product Images NDC 70518-4569

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4569). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This text provides information on Pregabalin Capsules manufactured by Rising Pharma, Inc. The medication comes in a 225mg dosage with 90 capsules per quantity. The usual dosage instructions are recommended to be checked in the insert included. It is advised to store the capsules between 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). The text mentions that federal law prohibits the transfer of this drug to anyone other than the prescribed patient. The capsules are orange and white in color. The medication is repackaged by RemedyRepack Inc. located in Indiana, PA. For any more information or assistance, contact 724-465-8762.*

FDA Label Image

Pregabalin-chem-structure.jpg (Pregabalin Chem Structure)

FDA Label Image

Pregabalin-equation.jpg (Pregabalin Equation)

This data appears to be related to a medical formula or calculation involving the parameters "weight (kg)", "serum creatinine (mg/dL)", and potentially an adjustment factor for female patients (based on the multiplier 0.85). The specific purpose or context of this formula is not entirely clear.*

FDA Label Image

Pregabalin-fig-01.jpg (Pregabalin Fig 01)

FDA Label Image

Pregabalin-fig-02.jpg (Pregabalin Fig 02)

This text appears to be showing data related to the percentage of patients who showed improvement in pain after using Pregabalin at a dose of 160 mg for three days. The data includes different time points and the percentage of improvement in pain compared to baseline. It seems to be part of a study or a clinical trial related to the effectiveness of Pregabalin in managing pain.*

FDA Label Image

Pregabalin-fig-03.jpg (Pregabalin Fig 03)

FDA Label Image

Pregabalin-fig-04.jpg (Pregabalin Fig 04)

This text provides information about the improvement in pain experienced by patients who are parents. It mentions the use of Pregabalin at varying doses throughout the day and also references a placebo. The text seems to be describing the effectiveness of different medications in reducing pain from baseline levels.*

FDA Label Image

Pregabalin-fig-05.jpg (Pregabalin Fig 05)

This excerpt seems to describe a study comparing the effects of three different treatments: Fregabalin 100 mg three times a day, Pregataiin 80 mg three times a day, and a Placebo. The data provided shows the number of patients who improved under each treatment, along with the percentage of pain improvement from baseline. It also includes numerical values for patient improvement and percentage improvement in pain levels.*

FDA Label Image

Pregabalin-fig-06.jpg (Pregabalin Fig 06)

Not available.*

FDA Label Image

Pregabalin-fig-07.jpg (Pregabalin Fig 07)

FDA Label Image

Pregabalin-fig-08.jpg (Pregabalin Fig 08)

This text appears to be a statistical table showing different percentages for different groups or treatments. It includes percentages such as 40.6%, 29.1%, and 22.6%, along with the Responder Rate and details about the Placebo and different dosage levels in mg/kg/day. The table seems to be providing information about response rates to different treatments or interventions.*

FDA Label Image

Pregabalin-fig-09.jpg (Pregabalin Fig 09)

This text provides information on different doses of Pregabalin (a medication used to treat pain and seizures) and a placebo. It includes the daily doses and improvement percentages in pain from baseline for each dose group.*

FDA Label Image

Pregabalin-fig-10.jpg (Pregabalin Fig 10)

This description provides information on the estimated percentage of subjects without long-term reduction (LTR) for the two groups studied, which included Pregabalin and Placebo. The table also includes data for different days and the corresponding percentages of subjects without LTR for each group.*

FDA Label Image

Pregabalin-fig-11.jpg (Pregabalin Fig 11)

FDA Label Image

Pregabalin-fig-12.jpg (Pregabalin Fig 12)

This information presents the percentage of subjects improved over time, specifically from baseline to week 16 using Pregabalin compared to Placebo. The table provides data points showing improvement status at different intervals.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.